NIOX Group plc (LSE:NIOX) reported lower first-half Revenue as pharma trials income fell back from an unusually high comparative period, while clinical sales grew modestly. Alongside the results, the asthma testing specialist proposed a tender offer to return up to £12.5m to shareholders at 80p per share.

What was announced

NIOX Group (LSE:NIOX), which makes point-of-care FeNO testing devices used in the diagnosis and management of asthma and COPD, published interim results for the six months to 30 June 2026 and, in a separate announcement, a proposed tender offer.

Revenue fell 4.8% to £24.0m from £25.2m. Clinical revenue rose 3% to £20.6m (£20.0m), which the company described as broadly flat at constant currency. Pharma trials revenue fell 34.6% to £3.4m from £5.2m, which NIOX attributed to the normalisation of clinical trial activity after an unusually high comparative period and to prioritising inventory for the clinical Business ahead of the NIOX PRO rollout.

At constant currency, the Americas grew 6%, while APAC and EMEA each declined 1%. The company cited reimbursement cuts in China and a decline in Germany, partly offset by gains in Japan, Korea, Australia, Belgium and Portugal.

The numbers

  • Gross Margin of 71% (H1 2025: 70%)
  • Adjusted EBITDA of £8.3m (£9.2m), a margin of 34.6% (36.5%)
  • Profit before tax of £6.0m (£5.9m)
  • Basic EPS of 1.41p (1.43p) and adjusted basic EPS of 1.98p (2.24p)

The group had cash of £16.8m and no Debt at 30 June, rising to £17.4m at 31 August. A final Dividend of 1.55p per share, totalling £6.5m, was paid in June. NIOX said it has returned around £60m to shareholders over four years.

Operationally, NIOX PRO has received a CE Mark and UK MHRA approval, and the company said the transition from NIOX VERO has been managed without Supply disruption. It also signed a 10-year exclusive sensor supply agreement and a master services agreement with a leading Clinical Trials services provider, which it said improves visibility of pharma trials revenue.

The tender offer

The proposed tender offer is for up to 15,625,000 ordinary shares, about 3.7% of the issued share capital, at 80p each, for a maximum of £12.5m. The price represents a 22.0% premium to the closing mid-market price of 65.6p and a 26.9% premium to the three-month volume-weighted average price of 63.1p.

Singer Capital Markets will buy tendered shares as principal and sell them to NIOX under a repurchase agreement; all shares bought back will be cancelled. Eligible shareholders may tender a basic entitlement of about 3.7% of their holdings, with tenders above that level satisfied only to the extent others do not take up their entitlements, and scaled back proportionately if required. Shareholders in restricted jurisdictions, including the US, Canada and Australia, are excluded. The board linked the offer to its cash generation and Balance Sheet position and its policy to "return 80% of free Cash Flow to shareholders in the medium term". On the company's figures, pro forma cash after the tender would be about £5.0m.

The tender opens on 30 September and closes at 1pm on 20 October 2026. A general meeting at 11am on 21 October must pass a special resolution, requiring 75% support. Results are due on 22 October, with CREST settlement by 27 October and cheques by 3 November. Directors intend to vote in favour and to tender 357,043 shares, about 0.1% of the issued capital.

What to watch next

Chief executive Jonathan Emms said the board "remains confident of delivering full-year revenue and adjusted EBITDA in line with current consensus market expectations", with the second half expected to be better than the first. The company cited the NIOX PRO rollout, increased clinical trial activity and regulatory submissions in the US and Japan. The general meeting vote and the tender take-up are the immediate milestones.